63459-910 : Granix 300 ug/.5ml Subcutaneous Injection, Solution


NDC63459-910
Labeler: Cephalon, Inc.
Product Type: Human Prescription Drug
Drug Name:  Granix
Dosage Form: Subcutaneous Injection, Solution
Application #: BLA125294
Rev. Date: 


NDC Package Codes:

  • 63459-910-11: 1 BLISTER PACK IN 1 CARTON (63459‑910‑11) > 1 SYRINGE, GLASS IN 1 BLISTER PACK (63459‑910‑12) > .5 ML IN 1 SYRINGE, GLASS (63459‑910‑01)
  • 63459-910-15: 10 BLISTER PACK IN 1 CARTON (63459‑910‑15) > 1 SYRINGE, GLASS IN 1 BLISTER PACK (63459‑910‑12) > .5 ML IN 1 SYRINGE, GLASS (63459‑910‑01)
  • 63459-910-17: 1 SYRINGE, GLASS IN 1 CARTON (63459‑910‑17) > .5 ML IN 1 SYRINGE, GLASS (63459‑910‑18)
  • 63459-910-36: 5 SYRINGE, GLASS IN 1 CARTON (63459‑910‑36) > .5 ML IN 1 SYRINGE, GLASS (63459‑910‑18)

Active Ingredients:

  • Filgrastim

Dosage Strength:

  • 300 ug/.5mL

Pharmaceutical Classes:

  • Granulocyte Colony-Stimulating Factor [CS]
  • Granulocyte-Macrophage Colony-Stimulating Factor [CS]
  • Increased Myeloid Cell Production [PE]
  • Leukocyte Growth Factor [EPC]

Related Products:

Based on records with the same trade name.
  • 63459-912 Granix 480 ug/.8ml Subcutaneous Injection, Solution by Cephalon, Inc.
  • 63459-918 Granix 300 ug/ml Subcutaneous Injection, Solution by Cephalon, Inc.
  • 63459-920 Granix 480 ug/1.6ml Subcutaneous Injection, Solution by Cephalon, Inc.

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 63459-910 QR Code

< Prev: 63459-701Next: 63459-912 >

Related Discussions:

TBone
Wanted to learn about Oxy ## I have found a pink pill that looks a lot like a fat tylonol and has the number 890 on one ... 1 reply




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.